145 related articles for article (PubMed ID: 7923128)
1. A pharmacokinetic model of topotecan clearance from plasma and cerebrospinal fluid.
Sung C; Blaney SM; Cole DE; Balis FM; Dedrick RL
Cancer Res; 1994 Oct; 54(19):5118-22. PubMed ID: 7923128
[TBL] [Abstract][Full Text] [Related]
2. Plasma and cerebrospinal fluid pharmacokinetic study of topotecan in nonhuman primates.
Blaney SM; Cole DE; Balis FM; Godwin K; Poplack DG
Cancer Res; 1993 Feb; 53(4):725-7. PubMed ID: 8428353
[TBL] [Abstract][Full Text] [Related]
3. Phase I/pharmacokinetic study of topotecan by 24-hour continuous infusion weekly.
Haas NB; LaCreta FP; Walczak J; Hudes GR; Brennan JM; Ozols RF; O'Dwyer PJ
Cancer Res; 1994 Mar; 54(5):1220-6. PubMed ID: 8118810
[TBL] [Abstract][Full Text] [Related]
4. Pharmacokinetics and pharmacodynamics of topotecan in patients with advanced cancer.
Grochow LB; Rowinsky EK; Johnson R; Ludeman S; Kaufmann SH; McCabe FL; Smith BR; Hurowitz L; DeLisa A; Donehower RC
Drug Metab Dispos; 1992; 20(5):706-13. PubMed ID: 1358575
[TBL] [Abstract][Full Text] [Related]
5. Cerebrospinal fluid pharmacokinetics and penetration of continuous infusion topotecan in children with central nervous system tumors.
Baker SD; Heideman RL; Crom WR; Kuttesch JF; Gajjar A; Stewart CF
Cancer Chemother Pharmacol; 1996; 37(3):195-202. PubMed ID: 8529278
[TBL] [Abstract][Full Text] [Related]
6. Plasma and cerebrospinal fluid pharmacokinetic study of BNP1350 in nonhuman primates.
Thompson PA; Berg SL; Aleksic A; Kerr JZ; McGuffey L; Dauser R; Nuchtern JG; Hausheer F; Blaney SM
Cancer Chemother Pharmacol; 2004 Jun; 53(6):527-32. PubMed ID: 14997342
[TBL] [Abstract][Full Text] [Related]
7. [Pharmacokinetics of SK & F 104864 in experimental animals. I. Plasma level].
Fujita H; Okamoto M; Takao A; Abe H; Ishii R; Takeda K
Gan To Kagaku Ryoho; 1995 Oct; 22(12):1783-7. PubMed ID: 7574810
[TBL] [Abstract][Full Text] [Related]
8. Topotecan lacks third space sequestration.
Gelderblom H; Loos WJ; Verweij J; de Jonge MJ; Sparreboom A
Clin Cancer Res; 2000 Apr; 6(4):1288-92. PubMed ID: 10778953
[TBL] [Abstract][Full Text] [Related]
9. Limited sampling model for area under the concentration time curve of total topotecan.
Minami H; Beijnen JH; Verweij J; Ratain MJ
Clin Cancer Res; 1996 Jan; 2(1):43-6. PubMed ID: 9816088
[TBL] [Abstract][Full Text] [Related]
10. Intrathecal administration of topotecan in nonhuman primates.
Blaney SM; Cole DE; Godwin K; Sung C; Poplack DG; Balis FM
Cancer Chemother Pharmacol; 1995; 36(2):121-4. PubMed ID: 7767947
[TBL] [Abstract][Full Text] [Related]
11. Plasma and cerebrospinal fluid pharmacokinetics of intravenous oxaliplatin, cisplatin, and carboplatin in nonhuman primates.
Jacobs SS; Fox E; Dennie C; Morgan LB; McCully CL; Balis FM
Clin Cancer Res; 2005 Feb; 11(4):1669-74. PubMed ID: 15746072
[TBL] [Abstract][Full Text] [Related]
12. Phase I clinical and plasma and cellular pharmacological study of topotecan without and with granulocyte colony-stimulating factor.
Abbruzzese JL; Madden T; Sugarman SM; Ellis AL; Loughlin S; Hess KR; Newman RA; Zwelling LA; Raber MN
Clin Cancer Res; 1996 Sep; 2(9):1489-97. PubMed ID: 9816325
[TBL] [Abstract][Full Text] [Related]
13. Clinical pharmacokinetics of topotecan.
Herben VM; ten Bokkel Huinink WW; Beijnen JH
Clin Pharmacokinet; 1996 Aug; 31(2):85-102. PubMed ID: 8853931
[TBL] [Abstract][Full Text] [Related]
14. A four-hour topotecan infusion achieves cytotoxic exposure throughout the neuraxis in the nonhuman primate model: implications for treatment of children with metastatic medulloblastoma.
Zamboni WC; Gajjar AJ; Mandrell TD; Einhaus SL; Danks MK; Rogers WP; Heideman RL; Houghton PJ; Stewart CF
Clin Cancer Res; 1998 Oct; 4(10):2537-44. PubMed ID: 9796988
[TBL] [Abstract][Full Text] [Related]
15. Pediatric phase I trial and pharmacokinetic study of topotecan administered as a 24-hour continuous infusion.
Blaney SM; Balis FM; Cole DE; Craig C; Reid JM; Ames MM; Krailo M; Reaman G; Hammond D; Poplack DG
Cancer Res; 1993 Mar; 53(5):1032-6. PubMed ID: 8439950
[TBL] [Abstract][Full Text] [Related]
16. Pharmacokinetics of tiazofurin in the plasma and cerebrospinal fluid of rhesus monkeys.
Grygiel JJ; Balis FM; Collins JM; Lester CM; Poplack DG
Cancer Res; 1985 May; 45(5):2037-9. PubMed ID: 3986760
[TBL] [Abstract][Full Text] [Related]
17. Pharmacokinetics and pharmacodynamics of topotecan administered daily for 5 days every 3 weeks.
van Warmerdam LJ; Verweij J; Schellens JH; Rosing H; Davies BE; de Boer-Dennert M; Maes RA; Beijnen JH
Cancer Chemother Pharmacol; 1995; 35(3):237-45. PubMed ID: 7805183
[TBL] [Abstract][Full Text] [Related]
18. Topotecan vitreous levels after periocular or intravenous delivery in rabbits: an alternative for retinoblastoma chemotherapy.
Carcaboso AM; Bramuglia GF; Chantada GL; Fandiño AC; Chiappetta DA; de Davila MT; Rubio MC; Abramson DH
Invest Ophthalmol Vis Sci; 2007 Aug; 48(8):3761-7. PubMed ID: 17652749
[TBL] [Abstract][Full Text] [Related]
19. Phase I dose-finding study and a pharmacokinetic/pharmacodynamic analysis of the neutropenic response of intravenous diflomotecan in patients with advanced malignant tumours.
Trocòniz IF; Garrido MJ; Segura C; Cendrós JM; Principe P; Peraire C; Obach R
Cancer Chemother Pharmacol; 2006 Jun; 57(6):727-35. PubMed ID: 16261364
[TBL] [Abstract][Full Text] [Related]
20. Plasma and cerebrospinal fluid pharmacokinetics of 9-aminocamptothecin (9-AC), irinotecan (CPT-11), and SN-38 in nonhuman primates.
Blaney SM; Takimoto C; Murry DJ; Kuttesch N; McCully C; Cole DE; Godwin K; Balis FM
Cancer Chemother Pharmacol; 1998; 41(6):464-8. PubMed ID: 9554590
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
